SG11202011313UA - Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins - Google Patents
Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteinsInfo
- Publication number
- SG11202011313UA SG11202011313UA SG11202011313UA SG11202011313UA SG11202011313UA SG 11202011313U A SG11202011313U A SG 11202011313UA SG 11202011313U A SG11202011313U A SG 11202011313UA SG 11202011313U A SG11202011313U A SG 11202011313UA SG 11202011313U A SG11202011313U A SG 11202011313UA
- Authority
- SG
- Singapore
- Prior art keywords
- knock
- cells
- generation
- out primary
- expanded human
- Prior art date
Links
- 102000004389 Ribonucleoproteins Human genes 0.000 title 1
- 108010081734 Ribonucleoproteins Proteins 0.000 title 1
- 101150038500 cas9 gene Proteins 0.000 title 1
- 210000000822 natural killer cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862672368P | 2018-05-16 | 2018-05-16 | |
PCT/US2019/032670 WO2019222503A1 (en) | 2018-05-16 | 2019-05-16 | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011313UA true SG11202011313UA (en) | 2020-12-30 |
Family
ID=68541163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011313UA SG11202011313UA (en) | 2018-05-16 | 2019-05-16 | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210228630A1 (en) |
EP (1) | EP3796924A4 (en) |
JP (2) | JP2021523725A (en) |
KR (1) | KR20210013077A (en) |
CN (1) | CN113518826A (en) |
AU (1) | AU2019271366A1 (en) |
BR (1) | BR112020023232A2 (en) |
CA (1) | CA3100341A1 (en) |
IL (1) | IL278723B2 (en) |
MX (1) | MX2020012208A (en) |
SG (1) | SG11202011313UA (en) |
WO (1) | WO2019222503A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220093337A (en) * | 2019-10-31 | 2022-07-05 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | Generation of CD38 Knockout Primary and Expanded Human NK Cells |
CN116018148A (en) * | 2020-03-11 | 2023-04-25 | 全国儿童医院研究所 | NK cells and their use for the treatment of microbial infections |
MX2022012792A (en) * | 2020-04-30 | 2023-02-14 | Res Institute At Nationwide Children´S Hospital | Overcoming immune suppression with tgf-î² resistant nk cells. |
CN111607569A (en) * | 2020-06-01 | 2020-09-01 | 广东昭泰体内生物医药科技有限公司 | Method for reprogramming ITNK cells based on CRISPR/Cas9 |
JP2023531729A (en) * | 2020-06-26 | 2023-07-25 | シーエスエル・ベーリング・エルエルシー | Donor T cells with kill switches |
EP4362957A1 (en) | 2021-07-01 | 2024-05-08 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
WO2023081200A2 (en) * | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3018200A1 (en) * | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
US20180171298A1 (en) * | 2015-06-30 | 2018-06-21 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
CN116064401A (en) * | 2015-07-29 | 2023-05-05 | 昂克医疗有限公司 | Modified natural killer cells and natural killer cell lines with enhanced cytotoxicity |
WO2017023801A1 (en) * | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
US20200208111A1 (en) * | 2016-06-09 | 2020-07-02 | Branden S. Moriarity | Genome-edited nk cell and methods of making and using |
EP3487991B1 (en) * | 2016-07-25 | 2022-09-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing modified natural killer cells and methods of use |
US10799536B2 (en) * | 2016-12-09 | 2020-10-13 | Onk Therapeutics Limited | Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38 |
MX2019007840A (en) * | 2016-12-30 | 2020-08-03 | Celularity Inc | Genetically modified natural killer cells. |
WO2018213828A1 (en) * | 2017-05-19 | 2018-11-22 | Case Western Reserve University | Compositions and methods for expanding ex vivo natural killer cells and therapeutic uses thereof |
KR20210005240A (en) * | 2018-05-03 | 2021-01-13 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blocking |
-
2019
- 2019-05-16 SG SG11202011313UA patent/SG11202011313UA/en unknown
- 2019-05-16 JP JP2020564266A patent/JP2021523725A/en active Pending
- 2019-05-16 WO PCT/US2019/032670 patent/WO2019222503A1/en unknown
- 2019-05-16 KR KR1020207035445A patent/KR20210013077A/en active Search and Examination
- 2019-05-16 MX MX2020012208A patent/MX2020012208A/en unknown
- 2019-05-16 CN CN201980045876.9A patent/CN113518826A/en active Pending
- 2019-05-16 EP EP19804411.7A patent/EP3796924A4/en active Pending
- 2019-05-16 BR BR112020023232-7A patent/BR112020023232A2/en unknown
- 2019-05-16 CA CA3100341A patent/CA3100341A1/en active Pending
- 2019-05-16 AU AU2019271366A patent/AU2019271366A1/en active Pending
- 2019-05-16 IL IL278723A patent/IL278723B2/en unknown
- 2019-05-16 US US17/055,837 patent/US20210228630A1/en active Pending
-
2024
- 2024-03-07 JP JP2024034817A patent/JP2024075618A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113518826A (en) | 2021-10-19 |
AU2019271366A1 (en) | 2021-01-14 |
WO2019222503A1 (en) | 2019-11-21 |
JP2021523725A (en) | 2021-09-09 |
EP3796924A4 (en) | 2022-01-12 |
IL278723A (en) | 2021-03-01 |
BR112020023232A2 (en) | 2021-02-23 |
IL278723B1 (en) | 2024-03-01 |
KR20210013077A (en) | 2021-02-03 |
US20210228630A1 (en) | 2021-07-29 |
MX2020012208A (en) | 2021-03-02 |
EP3796924A1 (en) | 2021-03-31 |
IL278723B2 (en) | 2024-07-01 |
CA3100341A1 (en) | 2019-11-21 |
JP2024075618A (en) | 2024-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL278723A (en) | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins | |
EP4051297A4 (en) | Generation of cd38 knock-out primary and expanded human nk cells | |
EP3638157A4 (en) | Expandable intervertebral implant and related methods | |
IL271261A (en) | Expandable sheath and methods of using the same | |
EP3400557A4 (en) | Webinterface generation and testing using artificial neural networks | |
EP3368660A4 (en) | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells | |
EP3688382A4 (en) | Systems and methods of generating electricity using heat from within the earth | |
IL284196A (en) | Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias | |
EP3659388A4 (en) | Methods and related devices for secondary node addition | |
GB2571871B (en) | Asynchronous local and remote generation of consistent point-in-time snap copies | |
ZA201805917B (en) | Expandable stent and methods of crimping and expanding such stent | |
EP3532605A4 (en) | Improved generation of muscle lineage cells and therapeutic uses thereof | |
EP3582856A4 (en) | Compositions and methods for activating nk cells | |
IL273757A (en) | Expansion and use of expanded nk cell fractions | |
EP3675991A4 (en) | Free radical generator and methods of use | |
SG11202104334SA (en) | Two-gene vectors for generating car-t cells and uses thereof | |
EP3573242A4 (en) | Frequency generator and frequency generation method | |
EP3420075A4 (en) | Generation of cancer stem cells and use thereof | |
SG11202007370RA (en) | Car-t cells and autoimmune diseases | |
IL273978B2 (en) | Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene | |
EP3307873A4 (en) | Hematopoietic cells and methods of using and generating the same | |
EP3529397A4 (en) | Ozone generators, methods of making ozone generators, and methods of generating ozone | |
SG11202101468XA (en) | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto | |
EP3712268A4 (en) | Transformed human cell and use thereof | |
SG11202105217RA (en) | Placenta-derived allogeneic car-t cells and uses thereof |